Grant Number:	1R01CA292930-01A1 Interpret this number
Primary Investigator:	Hoshida, Yujin
Organization:	Ut Southwestern Medical Center
Project Title:	Non-Invasive Etiology-Adjusted Precision Liver Cancer Risk Prediction
Fiscal Year:	2025

Hepatocellular carcinoma (HCC) is the major histological type of liver cancer, caused by viral (HBV, HCV) and metabolic (alcohol, metabolic dysfunction-associated steatotic liver disease [MASLD]) etiologies. The high mortality rate is attributable to failed early cancer detection, which is increasingly challenging for the current “one-size-fits-all” HCC screening owing to the rapidly changing etiological landscape and growing etiologically heterogeneous at-risk patient populations. Our prior simulation study showed that individual risk-based HCC screening is cost-effective. However, new tools to precisely evaluate the risk according to confounding factors, particularly etiology, are urgently needed. We previously developed etiology-agnostic HCC risk biomarkers, hepatic transcriptome-based Prognostic Liver Signature (PLS) and serum proteome-based Prognostic Liver Secretome signature (PLSec), which were successfully validated in phase 3 biomarker studies. Subsequently, we developed etiology-specific “plug-in” biomarkers for patients with cured HCV and MASLD, which substantially improve the etiology-agnostic HCC risk prediction. PLS/PLSec family biomarkers are therapeutically modifiable, and used as endpoints in clinical trials and studies of HCC chemopreventive agents. These results warrant further expansion of this approach to other major etiologies, HBV and ALD, and non- cirrhotic MASLD for comprehensive etiology-adjusted HCC risk prediction. Cholangiocarcinoma (CCA) risk factors remain largely unknown, as evidenced by the absence of clinically recognizable risk conditions in approximately half of the CCA patients, highlighting an urgent unmet need for CCA risk biomarkers. To address these unmet needs, our objectives are to develop a strategy for HCC risk assessment in cirrhosis and non- cirrhosis patients with the major viral and metabolic etiologies, and develop resources for CCA risk biomarker discovery. Aim 1. Develop and validate etiology-specific HCC risk biomarkers in cirrhotic and non-cirrhotic chronic liver disease patients: we will develop and validate tissue/serum-based “plug-in” HCC risk biomarkers and their integration with the etiology-agnostic PLSec as etiology-adjusted HCC risk assessment tools in cirrhosis and non-cirrhosis patients with HBV, ALD, and MASLD. Tissue/serum samples for CCA risk biomarker development will also be collected. Aim 2. Determine cost-effectiveness of etiology-adjusted HCC screening: by utilizing our established Markov models, we will determine the clinical utility of etiology-adjusted risk- stratified HCC screening, and identify optimal individualized screening strategies. We expect to establish a new strategy of comprehensive etiology-adjusted HCC risk prediction and resources for CCA risk biomarker discovery, which will collectively lead to a transformative improvement in the prognosis of this deadly cancer type.




Validation of Risk Models for Predicting Post-SVR HCC in Real-World Surveillance Across Global Geographic Regions.
Authors: Toyoda H. , Hoshida Y. , Parikh N.D. , Jalal P.K. , Piñero F. , Mendizabal M. , Ridruejo E. , Cheinquer H. , Casadei-Gardini A. , Kanneganti M. , et al. .
Source: Liver International : Official Journal Of The International Association For The Study Of The Liver, 2026 Jul; 46(7), p. e70734.
PMID: 42257496
Related Citations

Claudin-1 targeting suppresses tumor growth, invasion, and metastasis in patient-derived cholangiocarcinoma models.
Authors: Nehme Z. , Muller M. , Brochon J. , Crouchet E. , Jühling F. , Messé M. , Meiss-Heydmann L. , Moehlin J. , Desert R. , Del Zompo F. , et al. .
Source: Science Translational Medicine, 2026-06-03 00:00:00.0; 18(852), p. eadp2595.
EPub date: 2026-06-03 00:00:00.0.
PMID: 42234772
Related Citations

Development and validation of risk stratification models for hepatocellular cancer: A framework from the translational liver cancer consortium.
Authors: Kanwal F. , Feng Z. , Hoshida Y. , Chhatwal J. , Wong V.W. , Ioannou G.N. , Nahon P. , Lotter W. , Ning J. , Taouli B. , et al. .
Source: Hepatology (baltimore, Md.), 2026-04-20 00:00:00.0; , .
EPub date: 2026-04-20 00:00:00.0.
PMID: 42008824
Related Citations

Net benefit of surveillance varies by hepatocellular carcinoma risk in patients with cirrhosis.
Authors: Patel A. , Gavrila E. , Yekkaluri S. , Hoshida Y. , Hernaez R. , Singal A.G. .
Source: Jhep Reports : Innovation In Hepatology, 2026-03-25 00:00:00.0; 8(8), p. 101831.
EPub date: 2026-03-25 00:00:00.0.
PMID: 41895663
Related Citations

Chemoprevention of hepatocellular carcinoma by next-generation antipsychotic aripiprazole.
Authors: Slović N. , Mishra S. , Paul S. , Oudot M.A. , Jühling F. , Kanzaki H. , Moehlin J. , Charlot A. , Denos M. , Durand S.C. , et al. .
Source: Hepatology (baltimore, Md.), 2026-03-13 00:00:00.0; , .
EPub date: 2026-03-13 00:00:00.0.
PMID: 41838879
Related Citations

MVI-targeted carbon-ion radiotherapy combined with immunotherapy for advanced hepatocellular carcinoma: Phase Ib DEPARTURE trial.
Authors: Ogasawara S. , Koroki K. , Makishima H. , Wakatsuki M. , Takahashi A. , Fujiya M. , Yumita S. , Nakagawa M. , Kanzaki H. , Kobayashi K. , et al. .
Source: Jhep Reports : Innovation In Hepatology, 2026-02-05 00:00:00.0; 8(5), p. 101765.
EPub date: 2026-02-05 00:00:00.0.
PMID: 41904890
Related Citations

Research Communication: Serum Metabolomic Signatures Predict Tumour Recurrence After Resection or Ablation in Patients With Early-Stage Hepatocellular Carcinoma.
Authors: Arvind A. , Kanzaki H. , Ahmed F. , Fujiwara N. , Hoshida Y. , Singal A.G. .
Source: Alimentary Pharmacology & Therapeutics, 2026 Feb; 63(3), p. 414-418.
EPub date: 2025-08-26 00:00:00.0.
PMID: 40875577
Related Citations

The efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in relation to tumor-infiltrating lymphocytes.
Authors: Kanzaki H. , Ishino T. , Ogasawara S. , Tsuchiya T. , Fujiya M. , Sawada M. , Izai R. , Akatsuka T. , Miwa C. , Yonemoto T. , et al. .
Source: Jhep Reports : Innovation In Hepatology, 2025 Dec; 7(12), p. 101614.
EPub date: 2025-10-01 00:00:00.0.
PMID: 41362708
Related Citations

Performance of GAAD and GALAD Biomarker Panels for HCC Detection in Patients with MASLD or ALD Cirrhosis.
Authors: Jarrah M. , Deodhar S. , Quirk L. , Al-Hasan M. , Sharma A. , Bhamra G. , Terrell J. , Kanwal F. , Hoshida Y. , Rich N.E. , et al. .
Source: Cancers, 2025-11-29 00:00:00.0; 17(23), .
EPub date: 2025-11-29 00:00:00.0.
PMID: 41375033
Related Citations

Targeting peroxiredoxin 2 prevents hepatocarcinogenesis in metabolic liver disease models.
Authors: Crouchet E. , Schaeffer E. , Oudot M.A. , Moehlin J. , Gadenne C. , Jühling F. , El Saghire H. , Fujiwara N. , Zhu S. , Akter Rasha F. , et al. .
Source: The Journal Of Clinical Investigation, 2025-11-03 00:00:00.0; 135(21), .
EPub date: 2025-09-11 00:00:00.0.
PMID: 40932790
Related Citations

The Spatial Extracellular Proteomic Tumor Microenvironment Distinguishes Molecular Subtypes of Hepatocellular Carcinoma.
Authors: Macdonald J.K. , Taylor H.B. , Wang M. , Delacourt A. , Edge C. , Lewin D.N. , Kubota N. , Fujiwara N. , Rasha F. , Marquez C.A. , et al. .
Source: Journal Of Proteome Research, 2024-09-06 00:00:00.0; 23(9), p. 3791-3805.
EPub date: 2024-07-09 00:00:00.0.
PMID: 38980715
Related Citations